SCHEMBL431901

SCHEMBL431901

O=CCCCOCCCOCCCC=O

nearest known ligand 0.53

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.53
TSHR P16473 2/20 0.43
MAPT P10636 1/20 0.35
FAAH O00519 2/20 0.35
TRPV1 Q8NER1 2/20 0.35
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6545092 0.97 HIF1A (0.56) HIF1ATSHRMAPTFAAHTRPV1
SCHEMBL127719 0.94 HIF1A (0.53) HIF1ATSHRMAPTFAAHTRPV1
SCHEMBL10310587 0.91 HIF1A (0.50) HIF1ATSHRMAPTFAAHTRPV1
SCHEMBL302670 0.85 TSHR (0.50) HIF1ATSHRMAPTFAAHTRPV1
SCHEMBL3318201 0.85 TSHR (0.50) HIF1ATSHRMAPTFAAHTRPV1
SCHEMBL4556429 0.85 TSHR (0.50) HIF1ATSHRMAPTFAAHTRPV1
SCHEMBL3259629 0.85 TSHR (0.50) HIF1ATSHRMAPTFAAHTRPV1
SCHEMBL16568619 0.85 TSHR (0.50) HIF1ATSHRMAPTFAAHTRPV1
SCHEMBL5138631 0.84 HIF1A (0.43) HIF1ATSHRMAPTFAAHTRPV1
SCHEMBL5446361 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853325-B2 Water-soluble polymer alkanals NEKTAR THERAPEUTICS (US) 2014-10-07 US disclosed
US-20120065429-A1 WATER-SOLUBLE POLYMER ALKANALS NEKTAR THERAPEUTICS (US) 2012-03-15 US disclosed
US-8076412-B2 Water-soluble polymer alkanals NEKTAR THERAPEUTICS (US) 2011-12-13 US disclosed
US-20110034737-A1 Water-Soluble Polymer Alkanals NEKTAR THERAPEUTICS (US) 2011-02-10 US disclosed
US-7838595-B2 high purity; storage stability; electrophilically activated polymer derivatives with aldehyde functionality for conjugating to biologically active molecules; drug-polymer conjugate; NEKTAR THERAPEUTICS (US) 2010-11-23 US disclosed
US-20090234070-A1 high purity; storage stability; electrophilically activated polymer derivatives with aldehyde functionality for conjugating to biologically active molecules; drug-polymer conjugate; NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-09-17 US disclosed
US-7511094-B2 2-methylbutyraldehyde diethyl acetal end capped polyoxyethylene glycol; polyalkylene oxide, polyivnylpyrrolidone, polyvinyl alcohol, polyoxazoline etc. endcapped with polyetherpolyamine copolymers or oligomers covalently attached to diacetal tetramethylene group NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-03-31 US disclosed
US-7157546-B2 Polyoxyethylene glycol; purity, storage stability NEKTAR THERAPEUTICS AL, CORPORATION (US) 2007-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065429-A1 WATER-SOLUBLE POLYMER ALKANALS ALK, ALKBH3, AQP1 HIF1A 1407/4885TSHR 4866/4885MAPT 950/4885
US-20110034737-A1 Water-Soluble Polymer Alkanals ALK, ALKBH3, AQP1 HIF1A 1407/4885TSHR 4866/4885MAPT 950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.